Show simple item record

Authordc.contributor.authorHaye Salinas, M. J. 
Authordc.contributor.authorCaeiro, F. 
Authordc.contributor.authorSaurit, V. 
Authordc.contributor.authorNeira Quiroga, Óscar 
Admission datedc.date.accessioned2018-07-03T14:21:44Z
Available datedc.date.available2018-07-03T14:21:44Z
Publication datedc.date.issued2017
Cita de ítemdc.identifier.citationLupus (2017) 26, 1368–1377es_ES
Identifierdc.identifier.other10.1177/0961203317699284
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/149397
Abstractdc.description.abstractObjectives The objectives of this study were to examine the demographic and clinical features associated with the occurrence of pleuropulmonary manifestations, the predictive factors of their occurrence and their impact on mortality in systemic lupus erythematosus (SLE) patients. Materials and methods The association of pleuropulmonary manifestations with demographic and clinical features, the predictive factors of their occurrence and their impact on mortality were examined in GLADEL patients by appropriate univariable and multivariable analyses. Results At least one pleuropulmonary manifestation occurred in 421 of the 1480 SLE patients (28.4%), pleurisy being the most frequent (24.0%). Age at SLE onset 30 years (OR 1.42; 95% CI 1.10-1.83), the presence of lower respiratory tract infection (OR 3.19; 95% CI 2.05-4.96), non-ischemic heart disease (OR 3.17; 95% CI 2.41-4.18), ischemic heart disease (OR 3.39; 95% CI 2.08-5.54), systemic (OR 2.00; 95% CI 1.37-2.91), ocular (OR 1.58; 95% CI 1.16-2.14) and renal manifestations (OR 1.44; 95% CI 1.09-1.83) were associated with pleuropulmonary manifestations, whereas cutaneous manifestations were negatively associated (OR 0.47; 95% CI 0.29-0.76). Non-ischemic heart disease (HR 2.24; 95% CI 1.63-3.09), SDI scores 1 (OR 1.54; 95% CI 1.10-2.17) and anti-La antibody positivity (OR 2.51; 95% CI 1.39-4.57) independently predicted their subsequent occurrence. Cutaneous manifestations were protective of the subsequent occurrence of pleuropulmonary manifestations (HR 0.62; 95% CI 0.43-0.90). Pleuropulmonary manifestations independently contributed a decreased survival (HR: 2.79 95% CI 1.80-4.31). Conclusion Pleuropulmonary manifestations are frequent in SLE, particularly pleuritis. Older age, respiratory tract infection, cardiac, systemic and renal involvement were associated with them, whereas cutaneous manifestations were negatively associated. Cardiac compromise, SDI scores 1 and anti-La positivity at disease onset were predictive of their subsequent occurrence, whereas cutaneous manifestations were protective. They independently contributed to a decreased survival in these patients.es_ES
Patrocinadordc.description.sponsorshipPan American League of Associations for Rheumatology (PANLAR) Federico Wilhelm Agricola Foundation Researches_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherSage Publicationses_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Sourcedc.sourceLupuses_ES
Keywordsdc.subjectEpidemiologyes_ES
Keywordsdc.subjectPulmonary systemic lupus erythematosuses_ES
Títulodc.titlePleuropulmonary involvement in patients with systemic lupus erythematosus from a Latin American inception cohort (GLADEL)es_ES
Document typedc.typeArtículo de revista
Catalogueruchile.catalogadortjnes_ES
Indexationuchile.indexArtículo de publicación ISIes_ES


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile